#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

CAR-T therapies were hailed as a breakthrough when Novartis received the first FDA approval for Kymriah back in 2017. Though highly effective at treating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

Sign up to read this article for free.

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Cell ther­a­py start­up A2 Bio­ther­a­peu­tics nets $80M Se­ries C

Ley­den Labs gets $70M to test if nasal sprays can help pro­tect against virus­es

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses